OnCusp is actively expanding its portfolio of oncology assets. We partner with biotechnology firms, pharmaceutical companies, and academic researchers seeking to accelerate development of their first-in-class or global top 3 preclinical assets. Partnership models and deal structures are flexible, but we are always guided by our core principle that maximum value creation occurs when interests are aligned. Our capital-efficient model, rigorous clinical trials, and global licensing network can unlock the best outcome possible for partnered assets.
If you would like to learn more about our work or would like to explore specific partnership opportunities, please contact us today:
OnCusp has closed an oversubscribed seed round financing of $25m from investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, and AIHC Capital.